IP Library › Granted Patent US 12,359,202
Granted Patent B2
US 12,359,202 · App. 18/773,461 · Granted Jul 15, 2025

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Inventors: Beatrice Diana Darimont (San Diego, CA); Usue Etxaniz Irigoien (San Diego, CA); Venkata Ramana Doppalapudi (San Diego, CA); Michael Caramian Cochran (La Jolla, CA); Isaac Marks (San Diego, CA); Tyler Albin (San Diego, CA)
Assignee: AVIDITY BIOSCIENCES, INC.
C12N15/113A61K31/7125A61K39/3955A61K47/6807A61K47/6849A61P21/00C07K16/2881C07K19/00A61K2039/505A61K47/68A61K47/6811C12N2310/314C12N2310/3233C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,359,202
App. No.
18/773,461
Granted
Jul 15, 2025
Kind
B2
Abstract

Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.

Claims (24)

1. An antisense oligonucleotide conjugate comprising an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to an antisense oligonucleotide, wherein the antisense oligonucleotide consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 116-119.

2. The antisense oligonucleotide conjugate of claim 1 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, monoclonal antibody or antigen binding fragment thereof, monovalent Fab′, divalent Fab 2 , single chain variable fragment (scFv), diabody, minibody, nanobody, single domain antibody (sdAb), or camelid antibody or antigen binding fragment thereof.

3. The antisense oligonucleotide conjugate of claim 1 , wherein the antisense oligonucleotide is conjugated to the anti-transferrin receptor antibody or antigen binding fragment thereof via a linker.

4. The antisense oligonucleotide conjugate of claim 3 , wherein the linker is a cleavable linker or a non-cleavable linker, wherein the linker is a heterobifunctional linker or a homobifunctional linker, and wherein the linker comprises a maleimide group, a dipeptide moiety, a benzoic acid group or derivatives thereof, a C1-C6 alkyl group, or a combination thereof.

5. The antisense oligonucleotide conjugate of claim 1 , wherein the antisense oligonucleotide conjugate has a ratio of the antisense oligonucleotide and the anti-transferrin receptor antibody or antigen binding fragment thereof as 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or higher.

6. The antisense oligonucleotide conjugate of claim 5 , wherein the antisense oligonucleotide conjugate has the ratio as 4 or 8 on average.

7. A method of treating muscular dystrophy in a subject in need thereof comprising administering to the subject an antisense oligonucleotide conjugate comprising an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to an antisense oligonucleotide, wherein the antisense oligonucleotide consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 116-119, wherein the antisense oligonucleotide induces exon 44 skipping in a pre-mRNA transcript of a DMD gene to generate an mRNA transcript encoding a truncated dystrophin protein.

8. The method of claim 7 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, monoclonal antibody or antigen binding fragment thereof, monovalent Fab′, divalent Fab 2 , single chain variable fragment (scFv), diabody, minibody, nanobody, single domain antibody (sdAb), or camelid antibody or antigen binding fragment thereof.

9. The method of claim 7 , wherein the antisense oligonucleotide is conjugated to the anti-transferrin receptor antibody or antigen binding fragment thereof via a linker.

10. The method of claim 9 , wherein the linker is a cleavable linker or a non-cleavable linker, wherein the linker is a heterobifunctional linker or a homobifunctional linker, and wherein the linker comprises a maleimide group, a dipeptide moiety, a benzoic acid group or derivatives thereof, a C1-C6 alkyl group, or a combination thereof.

11. The method of claim 7 , wherein the antisense oligonucleotide conjugate has a ratio of the antisense oligonucleotide and the anti-transferrin receptor antibody or antigen binding fragment thereof as 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or higher.

12. The method of claim 11 , wherein the antisense oligonucleotide conjugate has the ratio as 4 or 8 on average.

13. The method of claim 7 , wherein the antisense oligonucleotide conjugate is administered parenterally.

14. The method of claim 7 , wherein the truncated dystrophin protein modulates muscular dystrophy.

15. The method of claim 7 , wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy.

16. A method of inducing exon 44 skipping in a targeted pre-mRNA transcript of a DMD gene, comprising:

a) contacting a muscle cell with an antisense oligonucleotide conjugate comprising an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to an antisense oligonucleotide, wherein the antisense oligonucleotide consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 116-119, wherein the antisense oligonucleotide induces exon 44 skipping in the targeted pre-mRNA transcript, and wherein the antisense oligonucleotide conjugate is preferentially delivered into the muscle cell;

b) hybridizing the antisense oligonucleotide to the targeted pre-mRNA transcript to induce exon 44 skipping in the targeted pre-mRNA transcript; and

c) translating an mRNA transcript produced from the targeted pre-mRNA transcript processed in step b) in the muscle cell to generate a truncated dystrophin protein.

17. The method of claim 16 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, monoclonal antibody or antigen binding fragment thereof, monovalent Fab′, divalent Fab 2 , single chain variable fragment (scFv), diabody, minibody, nanobody, single domain antibody (sdAb), or camelid antibody or antigen binding fragment thereof.

18. The method of claim 16 , wherein the antisense oligonucleotide is conjugated to the anti-transferrin receptor antibody or antigen binding fragment thereof via a linker.

19. The method of claim 18 , wherein the linker is a cleavable linker or a non-cleavable linker, wherein the linker is a heterobifunctional linker or a homobifunctional linker, and wherein the linker comprises a maleimide group, a dipeptide moiety, a benzoic acid group or derivatives thereof, a C1-C6 alkyl group, or a combination thereof.

20. The method of claim 16 , wherein the antisense oligonucleotide conjugate has a ratio of the antisense oligonucleotide and the anti-transferrin receptor antibody or antigen binding fragment thereof as 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or higher.

21. The method of claim 20 , wherein the antisense oligonucleotide conjugate has the ratio as 4 or 8 on average.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2024
From: DARIMONT, BEATRICE DIANA; ETXANIZ IRIGOIEN, USUE; DOPPALAPUDI, VENKATA RAMANA; COCHRAN, MICHAEL CARAMIAN; MARKS, ISAAC; ALBIN, TYLER
To: AVIDITY BIOSCIENCES, INC.
Reel/Frame 068169/0068 →
Continuity (3)
Continuation 18130757 · Apr 4, 2023
Provisional Application 63327725 · Apr 5, 2022
Related Publication 20240368598A1 · Nov 7, 2024
References Cited (316)
US 5142047A · Summerton et al. · 1992 [cited by applicant]
US 5185444A · Summerton et al. · 1993 [cited by applicant]
US 5334711A · Sproat et al. · 1994 [cited by applicant]
US 5627053A · Usman et al. · 1997 [cited by applicant]
US 5716824A · Beigelman et al. · 1998 [cited by applicant]
US 5736557A · Hofheinz et al. · 1998 [cited by applicant]
US 5889136A · Scaringe et al. · 1999 [cited by applicant]
US 6008400A · Scaringe et al. · 1999 [cited by applicant]
US 6111086A · Scaringe · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6538124B1 · Idusogie et al. · 2003 [cited by applicant]
US 6821783B1 · Comely et al. · 2004 [cited by applicant]
US 6884869B2 · Senter et al. · 2005 [cited by applicant]
US 7364731B2 · Idusogie et al. · 2008 [cited by applicant]
US 7452987B2 · Giese et al. · 2008 [cited by applicant]
US 7498298B2 · Doronina et al. · 2009 [cited by applicant]
US 7833992B2 · Vargeese et al. · 2010 [cited by applicant]
US 7893245B2 · Giese et al. · 2011 [cited by applicant]
US 7923547B2 · McSwiggen et al. · 2011 [cited by applicant]
US 7943762B2 · Weller et al. · 2011 [cited by applicant]
US 8084582B2 · Dahiyat et al. · 2011 [cited by applicant]
US 8084598B1 · Bentwich · 2011 [cited by applicant]
US 8090542B2 · Khvorova et al. · 2012 [cited by applicant]
US 8202979B2 · McSwiggen et al. · 2012 [cited by applicant]
US 8273866B2 · McSwiggen et al. · 2012 [cited by applicant]
US 8288352B2 · Doronina et al. · 2012 [cited by applicant]
US 8324370B2 · Giese et al. · 2012 [cited by applicant]
US 8324371B2 · Popplewell et al. · 2012 [cited by applicant]
US 8361979B2 · Aartsma-Rus et al. · 2013 [cited by applicant]
US 8461325B2 · Popplewell et al. · 2013 [cited by applicant]
US 8501703B2 · Bennett et al. · 2013 [cited by applicant]
US 8501930B2 · Rozema et al. · 2013 [cited by applicant]
US 8609105B2 · Senter et al. · 2013 [cited by applicant]
US 8618277B2 · Beigelman et al. · 2013 [cited by applicant]
US 8648185B2 · McSwigen et al. · 2014 [cited by applicant]
US 8697688B2 · Howard et al. · 2014 [cited by applicant]
US 8895722B2 · Iversen et al. · 2014 [cited by applicant]
US 8933215B2 · Giese et al. · 2015 [cited by applicant]
US 8936910B2 · Mitsch et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9078911B2 · Lu · 2015 [cited by applicant]
US 9089614B2 · Lin et al. · 2015 [cited by applicant]
US 9096877B2 · Johnson et al. · 2015 [cited by applicant]
US 9139828B2 · Platenburg et al. · 2015 [cited by applicant]
US 9175286B2 · Wilton et al. · 2015 [cited by applicant]
US 9181551B2 · McSwiggen et al. · 2015 [cited by applicant]
US 9222092B2 · Giese et al. · 2015 [cited by applicant]
US 9228187B2 · Wilton et al. · 2016 [cited by applicant]
US 9243245B2 · De Kimpe et al. · 2016 [cited by applicant]
US 9243251B2 · Popplewell et al. · 2016 [cited by applicant]
US 9243252B2 · Popplewell et al. · 2016 [cited by applicant]
US 9249416B2 · Wilton et al. · 2016 [cited by applicant]
US 9260471B2 · Cancilla et al. · 2016 [cited by applicant]
US 9416361B2 · Iversen et al. · 2016 [cited by applicant]
US 9434948B2 · Sazani et al. · 2016 [cited by applicant]
US 9441229B2 · Wilton et al. · 2016 [cited by applicant]
US 9447415B2 · Wilton et al. · 2016 [cited by applicant]
US 9447417B2 · Sazani et al. · 2016 [cited by applicant]
US 9499818B2 · Van Deutekom · 2016 [cited by applicant]
US 9512424B2 · Watanabe et al. · 2016 [cited by applicant]
US 9528109B2 · De Kimpe et al. · 2016 [cited by applicant]
US 9605019B2 · Verdine et al. · 2017 [cited by applicant]
US 9657294B2 · Beigelman et al. · 2017 [cited by applicant]
US 9695211B2 · Wada et al. · 2017 [cited by applicant]
US 9695423B2 · Giese et al. · 2017 [cited by applicant]
US 9732344B2 · Beigelman et al. · 2017 [cited by applicant]
US 9765338B2 · Bennett et al. · 2017 [cited by applicant]
US 9771588B2 · McSwiggen et al. · 2017 [cited by applicant]
US 9796974B2 · Rajeev et al. · 2017 [cited by applicant]
US 9890379B2 · De Kimpe et al. · 2018 [cited by applicant]
US 9926557B2 · De Kimpe et al. · 2018 [cited by applicant]
US 9982257B2 · Butler et al. · 2018 [cited by applicant]
US 10000754B2 · Beigelman et al. · 2018 [cited by applicant]
US 10144931B2 · Enya et al. · 2018 [cited by applicant]
US 10179912B2 · De Visser et al. · 2019 [cited by applicant]
US 10533171B2 · Van Deutekom et al. · 2020 [cited by applicant]
US 10913800B2 · Darimont et al. · 2021 [cited by applicant]
US 10994020B2 · Levin et al. · 2021 [cited by applicant]
US 11028179B2 · Darimont et al. · 2021 [cited by applicant]
US 11179472B2 · Levin et al. · 2021 [cited by applicant]
US 11311627B1 · Levin et al. · 2022 [cited by applicant]
US 11400163B2 · Levin et al. · 2022 [cited by applicant]
US 12064483B2 · Levin et al. · 2024 [cited by applicant]
US 12071621B2 · Darimont et al. · 2024 [cited by applicant]
US 20020142980A1 · Thompson et al. · 2002 [cited by applicant]
US 20080311557A1 · Elsemore et al. · 2008 [cited by applicant]
US 20110081362A1 · Elledge et al. · 2011 [cited by applicant]
US 20110263686A1 · Wilton et al. · 2011 [cited by applicant]
US 20110294753A1 · De Kimpe et al. · 2011 [cited by applicant]
US 20110301218A1 · Bozzoni et al. · 2011 [cited by applicant]
US 20120065169A1 · Hanson et al. · 2012 [cited by applicant]
US 20120094299A1 · Ranum et al. · 2012 [cited by applicant]
US 20120172415A1 · Voit et al. · 2012 [cited by applicant]
US 20120270925A1 · Wilton et al. · 2012 [cited by applicant]
US 20130028919A1 · Howard et al. · 2013 [cited by applicant]
US 20130172238A1 · Mitsch et al. · 2013 [cited by applicant]
US 20130309256A1 · Lyon et al. · 2013 [cited by applicant]
US 20140127239A1 · Howard · 2014 [cited by applicant]
US 20140286970A1 · Jeffrey et al. · 2014 [cited by applicant]
US 20140294851A1 · Nguyen · 2014 [cited by applicant]
US 20140296321A1 · Iversen · 2014 [cited by applicant]
US 20140315862A1 · Kaye · 2014 [cited by applicant]
US 20150037360A1 · Smith · 2015 [cited by applicant]
US 20150105539A1 · Miao et al. · 2015 [cited by applicant]
US 20150105540A1 · Miao et al. · 2015 [cited by applicant]
US 20160002637A1 · Sazani et al. · 2016 [cited by applicant]
US 20160053262A1 · Platenburg et al. · 2016 [cited by applicant]
US 20160102135A1 · Escobar-Cabrera · 2016 [cited by applicant]
US 20160298111A1 · Bestwick et al. · 2016 [cited by applicant]
US 20160304864A1 · De Kimpe et al. · 2016 [cited by applicant]
US 20160304877A1 · Swayze et al. · 2016 [cited by applicant]
US 20160367687A1 · Manoharan et al. · 2016 [cited by applicant]
US 20170107512A1 · De Kimpe et al. · 2017 [cited by applicant]
US 20170204410A1 · Watanabe et al. · 2017 [cited by applicant]
US 20170204414A1 · Van Deutekom et al. · 2017 [cited by applicant]
US 20170342416A1 · McSwiggen et al. · 2017 [cited by applicant]
US 20180016574A1 · Bestwick et al. · 2018 [cited by applicant]
US 20180028554A1 · Van Deutekom et al. · 2018 [cited by applicant]
US 20180044675A1 · Watanabe et al. · 2018 [cited by applicant]
US 20180112214A1 · De Kimpe et al. · 2018 [cited by applicant]
US 20180127758A1 · Bennett · 2018 [cited by applicant]
US 20180163209A1 · Bennett et al. · 2018 [cited by applicant]
US 20180305689A1 · Sætrom et al. · 2018 [cited by applicant]
US 20190177723A1 · Dickson · 2019 [cited by applicant]
US 20190240346A1 · Sugo et al. · 2019 [cited by applicant]
US 20190330626A1 · Rigo et al. · 2019 [cited by applicant]
US 20200028074A1 · Defferriere et al. · 2020 [cited by applicant]
US 20200282074A1 · Levin et al. · 2020 [cited by applicant]
US 20210395742A1 · MacPherson · 2021 [cited by applicant]
US 20220313833A1 · Levin et al. · 2022 [cited by applicant]
US 20230201363A1 · Geall et al. · 2023 [cited by applicant]
US 20230364256A1 · Darimont et al. · 2023 [cited by applicant]
US 20240175025A1 · Yokota et al. · 2024 [cited by applicant]
US 20240358736A1 · Levin et al. · 2024 [cited by applicant]
CN 106459955A · 2017 [cited by applicant]
EP 0336675A1 · 1989 [cited by applicant]
EP 0334656B1 · 1994 [cited by applicant]
EP 1579015A2 · 2005 [cited by applicant]
EP 1068241B1 · 2007 [cited by applicant]
EP 2119783A1 · 2009 [cited by applicant]
EP 2049664B1 · 2011 [cited by applicant]
EP 2278004B1 · 2012 [cited by applicant]
EP 2344637B1 · 2014 [cited by applicant]
EP 1423406B2 · 2015 [cited by applicant]
EP 3031920A1 · 2016 [cited by applicant]
EP 2421971B1 · 2016 [cited by applicant]
EP 2287306B2 · 2016 [cited by applicant]
EP 3030658A4 · 2017 [cited by applicant]
EP 2287305B2 · 2017 [cited by applicant]
EP 2486141B1 · 2018 [cited by applicant]
EP 2902406B1 · 2018 [cited by applicant]
EP 2595664B1 · 2018 [cited by applicant]
WO WO9104753A1 · 1991 [cited by applicant]
WO WO9207065A1 · 1992 [cited by applicant]
WO WO9315187A1 · 1993 [cited by applicant]
WO WO9726270A2 · 1997 [cited by applicant]
WO WO9734631A1 · 1997 [cited by applicant]
WO WO9813526A1 · 1998 [cited by applicant]
WO WO0149698A1 · 2001 [cited by applicant]
WO WO2006000057A1 · 2006 [cited by applicant]
WO WO2008036127A2 · 2008 [cited by applicant]
WO WO2009054725A2 · 2009 [cited by applicant]
WO WO2009099942A2 · 2009 [cited by applicant]
WO WO2009099991A2 · 2009 [cited by applicant]
WO WO2009139630A2 · 2009 [cited by applicant]
WO WO2009144481A2 · 2009 [cited by applicant]
WO WO2010048586A1 · 2010 [cited by applicant]
WO WO2011130371A1 · 2011 [cited by applicant]
WO WO2011150408A2 · 2011 [cited by applicant]
WO WO2014080251A1 · 2014 [cited by applicant]
WO WO2014140317A2 · 2014 [cited by applicant]
WO WO2014144978A2 · 2014 [cited by applicant]
WO WO2014145090A1 · 2014 [cited by applicant]
WO WO2014177042A1 · 2014 [cited by applicant]
WO WO2014197854A1 · 2014 [cited by applicant]
WO WO2015021457A2 · 2015 [cited by applicant]
WO WO2015038426A1 · 2015 [cited by applicant]
WO WO2015057699A2 · 2015 [cited by applicant]
WO WO2016187425A1 · 2016 [cited by applicant]
WO WO2016207240A1 · 2016 [cited by applicant]
WO WO2017148879A1 · 2017 [cited by applicant]
WO WO2017173408A1 · 2017 [cited by applicant]
WO WO2017192679A1 · 2017 [cited by applicant]
WO WO2017221883A1 · 2017 [cited by applicant]
WO WO2018002812A1 · 2018 [cited by applicant]
WO WO2018129384A1 · 2018 [cited by applicant]
WO WO2019060775A1 · 2019 [cited by applicant]
WO WO2021142313A1 · 2021 [cited by applicant]
WO WO2023283615A1 · 2023 [cited by applicant]
WO WO2023196400A2 · 2023 [cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Oct. 30, 2024. [cited by applicant]
Aartsma-Rus et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17(3):548-53 (2009). [cited by applicant]
Aartsma-Rus et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 12(Suppl 1):S71-7 (2002). [cited by applicant]
Abramova, Tatyana V. et al. Novel Oligonucleotide Analogues Based on Morpholino Nucleoside Subunits Antisense Technologies: New Chemical Possibilities. Indian Journal of Chemistry 48B:1721-1726 (2009). [cited by applicant]
Agarwal, Paresh. et al. A Pictet-Spengler Ligation for Protein Chemical Modification. PNAS USA 110(1):46-51 (2013). [cited by applicant]
Alegre, Maria-Luisa. et al. Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a “Humanized” OKT3 Monoclonal Antibody. Journal of Immunology 148(11):3461-3468 (1992). [cited by applicant]
Arechavala-Gomeza et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 18(9):798-810 (2007). [cited by applicant]
Axup, Jun Y. et al. Synthesis of Site-specific Antibody-drug Conjugates Using Unnatural Amino Acids. PNAS USA 109(40):16101-16106 (2012). [cited by applicant]
Beduneau et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 28(33):4978-4990 (2007). [cited by applicant]
Beigelman, Leonid et al. Chemical Modification of Hammerhead Ribozymes: Catalytic Activity and Nuclease Resistance. Journal of Biological Chemistry 270(43):25702-25708 (1995). [cited by applicant]
Bell et al. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the Ideal/Intact Gefitinib Trials. J Clin Oncol 23(31):8081-8092 (2005). [cited by applicant]
Bird, Robert E. et al. Single-chain Antigen-binding Proteins. Science 242(4877):423-426 (1988). [cited by applicant]
Blaney, Paul et al. Traceless Solid-phase Organic Synthesis. Chemical Reviews 102(7):2607-2624 (2002). [cited by applicant]
Brain and Development 42:117-123 (2010). [cited by applicant]
Burlina, Fabienne. et al. Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes. Bioorganic and Medicinal Chemistry 5(11):1999-2010 (1997). [cited by applicant]
Casi, Giulio. et al. Site-specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery. Journal of the American Chemical Society 134(13):5887-5892 (2012). [cited by applicant]
Clackson, Tim et al. Making Antibody Fragments using Phage Display Libraries. Nature 352(6336):624-628 (1991). [cited by applicant]
Colberre-Garapin, Florence et al. A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells. Journal of Molecular Biology 150(1):1-14 (1981). [cited by applicant]
Cole, S.P.C. et al. The EBV-Hybridoma Technique and its Application to Human Lung Cancer. Monoclonal Antibodies and Cancer Therapy 27:77-96 (1985). [cited by applicant]
Crouse, Gray F. et al. Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes. Molecular Cell Biology 3(2):257-266 (1983). [cited by applicant]
Darimont et al. 8-05 Abstract: A novel Antibody-Oligonucleotide Conjugate (AOC) platform enables efficient regulation of muscle targets in mice. Journal Of Cachexia, Sarcopenia And Muscle 8:999-1080 (2017). [cited by applicant]
Dawson, Philip E. et al. Modulation of Reactivity in Native Chemical Ligation through the Use of Thiol Additives. Journal of American Chemical Society 119(19):4325-4329 (1997). [cited by applicant]
Dawson, Philip E. et al. Synthesis of Proteins by Native Chemical Ligation. 266(5186):776-779 (1994). [cited by applicant]
De Angelis et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DM… [cited by applicant]
Debinski et al. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Research 52(19):5379-5385 (1992). [cited by applicant]
Den Dunnen et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet. 45(6):835-847 (1989). [cited by applicant]
Domingo et al. Transferrin receptor as a target for antibody—drug conjugates. Methods in Enzymology 112:238-247 (1985). [cited by applicant]
Earnshaw, David J. et al. Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function. Biopolymers (Nucleic Acid Sciences) 48(1):39-55 (1998). [cited by applicant]
Echigoya et al. In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. PLoS One 10(3):e0120058 (2015). [cited by applicant]
Feener et al. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 338:509-511 (Apr. 6, 1989). [cited by applicant]
Gao et al. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient mdx Mice. Mol Ther. 22(7):1333-1341 (2014). [cited by applicant]
Goldspiel, Barry R. et al. Human Gene Therapy. Clinical Pharmacy 12(7):488-505 (1993). [cited by applicant]
Gooding et al. Oligonucleotide conjugates—Candidates for gene silencing therapeutics. Eur J Pharm Biopharm. 107:321-40 (2016). [cited by applicant]
Griffey, Richard H et al. 2′-O-aminopropyl Ribonucleotides: A Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides. Journal of Medicinal Chemistry 39(2… [cited by applicant]
Hackeng, Tilman M. et al. Protein Synthesis by Native Chemical Ligation: Expanded Scope by Using Straightforward Methodology. PNAS USA 96(18):10068-10073 (1999). [cited by applicant]
Hanes, Jozef, and A Pluckthun. In Vitro Selection and Evolution of Functional Proteins by Using Ribosome Display. PNAS USA 94(10):4937-4942 (1997). [cited by applicant]
Hejesen, Christian et al. A Traceless Aryl-triazene Linker for DNA-directed Chemistry. Organic and Biomolecular Chemistry 11(15):2493-2497 (2013). [cited by applicant]
Hoffman et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle: Progress in Exon Skipping and Stop Codon Read Through. Am J Pathol 179(1):12-22 (2011). [cited by applicant]
Hudson et al. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharmaceuticals 182(1):49-58 (1999). [cited by applicant]
Huse, William D. et al. Generation Of A Large Combinatorial Library Of The Immunoglobulin Repertoire In Phage Lambda. Science 246(4935):1275-1281 (1989). [cited by applicant]
Idusogie, Esohe E. et al. Engineered Antibodies with Increased Activity to Recruit Complement. Journal of Immunology 166(4):2571-2575 (2001). [cited by applicant]
Ishikawa et al. Preparation of monomeric Fab'—horseradish peroxidase conjugate using thiol groups in the hinge and its evaluation in enzyme immunoassay and immunohistochemical staining. Ann N Y Acad Sci. 420:74-89 (1983… [cited by applicant]
Jearawiriyapaisarn et al. Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Mol Ther. 16(9): 1624-1629 (2008). [cited by applicant]
Kaneko, Etsuji et al. Optimizing Therapeutic Antibody Function: Progress with Fc Domain Engineering. Bio Drugs 25(1):1-11 (2011). [cited by applicant]
Karpeisky, Alexander et al. Highly Efficient Synthesis of 2-O-amino Nucleosides and their Incorporation in Hammerhead Ribozymes. Tetrahedron Letters 39:1131-1134 (1998). [cited by applicant]
Köhler, et al. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (1975). [cited by applicant]
Koizumi, Makoto. ENA Oligonucleotides as Therapeutics. Current Opinion in Molecular Therapeutics 8(2):144-149 (2006). [cited by applicant]
Kozbor, Danuta, and J C Roder. The Production of Monoclonal Antibodies From Human Lymphocytes. Immunology Today 4(3):72-79 (1983). [cited by applicant]
Kutmeier, G. et al. Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-round PCR. Biotechniques 17(2):242-246 (1994). [cited by applicant]
Lazar, Greg A. et al. Engineered Antibody Fc Variants with Enhanced Effector Function. PNAS USA 103(11):4005-4010 (2006). [cited by applicant]
Lee et al. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS One 13(5):e0197084 (2018). [cited by applicant]
Levin. Targeting Therapeutic Oligonucleotides. N Engl J Med 376:86-88 (2017). [cited by applicant]
Loakes, David. Survey and Summary: The applications of universal DNA base analogues. Nucleic Acids Research 29(12):2437-2447 (2001). [cited by applicant]
Lowy, Israel et al. Isolation of Transforming DNA: Cloning the Hamster Aprt Gene. Cell 22(3):817-823 (1980). [cited by applicant]
Lyon, Robert P. et al. Self-Hydrolyzing Maleimides improve the Stability and Pharmacological Properties of Antibody-drug Conjugates. Nature Biotechnology 32(10):1059-1062 (2014). [cited by applicant]
Martinez, Javier. et al. Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi. Cell 110(5):563-574 (2002). [cited by applicant]
Meregalli et al. Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26. BMC Med Genet 17(1):55 (2016). [cited by applicant]
Miyata et al. Polymer nanotechnology for nucleic acid delivery. Drug Delivery System 31(1):44-53 (2016) (English Abstract). [cited by applicant]
Moore, Gregory L. et al. Engineered Fc Variant Antibodies with Enhanced Ability to Recruit Complement and Mediate Effector Functions. mAbs 2(2):181-189 (2010). [cited by applicant]
Morgan, Richard A, and W F Anderson. Human Gene Therapy. Annual Review of Biochemistry 62:191-217 (1993). [cited by applicant]
Morrison, Sherie L. et al. Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains. PNAS USA 81(21):6851-6855 (1984). [cited by applicant]
Mulligan, Richard C, and P Berg. Selection for Animal Cells that Express the [cited by applicant]
Mulligan, Richard C. The Basic Science of Gene Therapy. Science 260(5110):926-932 (1993). [cited by applicant]
Natsume, Akito et al. Engineered Antibodies of IgG1/lgG3 Mixed Isotype with Enhanced Cytotoxic Activities. Cancer Research 68(10):3863-3872 (2008). [cited by applicant]
Neuberger, Michael S. et al. Recombinant Antibodies Possessing Novel Effector Functions. Nature 312(5995):604-608 (1984). [cited by applicant]
Normand-Sdiqui et al. Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX / 26) conjugates into an in vitro immortalised cell line model of the blood, brain barrier. Int J Pharmaceuticals 163:63-71… [cited by applicant]
Obika, Satosh et al. Synthesis of 2′-0,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Letters 38(50):8735-8738 (1997). [cited by applicant]
O'Hare, K. et al. Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase. PNAS USA 78(3):1527-1531 (1981). [cited by applicant]
PCT/US2018/012672 International Search Report and Written Opinion dated May 24, 2018. [cited by applicant]
PCT/US2018/012672 Invitation to Pay Additional Fees dated Mar. 20, 2018. [cited by applicant]
PCT/US2018/052289 International Search Report and Written Opinion dated Jan. 11, 2019. [cited by applicant]
PCT/US2023/017574 International Invitation to Pay Additional Fees dated Aug. 25, 2023. [cited by applicant]
PCT/US2023/017574 International Search Report and Written Opinion dated Oct. 31, 2023. [cited by applicant]
Perrault, Jean-Pierre et al. Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity. Nature 344(6266):565-568 (1990). [cited by applicant]
Pieken, Wolfgang A. et al. Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes. Science 253(5017):314-317 (1991). [cited by applicant]
Rhodes et al. Bicyclic Peptides as Next-Generation Therapeutics. Chemistry 23(52):12690-12703 (2017). [cited by applicant]
Santerre, Robert F. et al. Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-selection Markers in Mouse L Cells. Gene 30(3):147-156 (1984). [cited by applicant]
Schnyder et al. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377(Pt.1):61-67 (2004). [cited by applicant]
Schwarz, Dianne S. et al. Evidence that siRNAs Function as Guides, not Primers, in the [cited by applicant]
Sekyere et al. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochimica et Biophysica Acta 1722(2):131-142 (2005). [cited by applicant]
Shields, Robert L. et al. High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and design of IgG1 Variants with Improved Binding to the Fc Gamma R. Journal of … [cited by applicant]
Singh et al. Recent developments in oligonucleotide conjugation. Chem Soc Rev 39(6):2054-2070 (2010). [cited by applicant]
Skerra, Arne et al. Assembly of a Functional Immunoglobulin Fv Fragment in [cited by applicant]
Stavenhagen, Jeffrey B. et al. Enhancing the Potency of Therapeutic Monoclonal Antibodies via Fc Optimization. Advances in Enzyme Regulation 48:152-64 (2008). [cited by applicant]
Stavenhagen, Jeffrey B. et al. Fc Optimization of Therapeutic Antibodies Enhances their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcgamma Receptors. Cancer Res… [cited by applicant]
Strop, Pavel. et al. Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates. Chemistry and Biology 20(2):161-167 (2013). [cited by applicant]
Sugo et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control release 237:1-13 (2016). [cited by applicant]
Summerton, James et al. Morpholino Antisense Oligomers: Design, Preparation, and Properties. Antisense Nucleic Acid Drug Development 7(3):187-195 (1997). [cited by applicant]
Suñé-Pou et al. Targeting Splicing in the Treatment of Human Disease. Genes 8:E87 (2017). [cited by applicant]
Szybalska, Elizabeth H. et al. Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait. PNAS USA 48(12):2026-2034 (1962). [cited by applicant]
Takeda, Shin'ichi. Exon-skipping therapy for Duchenne muscular dystrophy. Clinical Neurology 51:914-916 (2011) (English Abstract). [cited by applicant]
Takeda, Shun-Ichi. et al. Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences. Nature 314(6010):452-454 (1985). [cited by applicant]
Tolstoshev, Paul. Gene Therapy, Concepts, Current Trials and Future Directions. Annual Review Pharmacology and Toxicology 32:573-596 (1993). [cited by applicant]
U.S. Appl. No. 16/128,450 Miscellaneous Communication re: Third Party Submission dated Jul. 1, 2019. [cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Apr. 19, 2019. [cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Apr. 30, 2020. [cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Dec. 16, 2020. [cited by applicant]
U.S. Appl. No. 16/128,450 Office Action dated Sep. 19, 2019. [cited by applicant]
U.S. Appl. No. 16/129,696 Miscellaneous Communication re: Third Party Submission dated Jul. 3, 2019. [cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Apr. 13, 2020. [cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Apr. 17, 2019. [cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Dec. 14, 2020. [cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated May 26, 2021. [cited by applicant]
U.S. Appl. No. 16/129,696 Office Action dated Sep. 19, 2019. [cited by applicant]
U.S. Appl. No. 16/649,572 Miscellaneous Communication re: Third Party Submission dated Mar. 19, 2021. [cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Apr. 16, 2024. [cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Aug. 31, 2023. [cited by applicant]
U.S. Appl. No. 16/649,572 Office Action dated Feb. 22, 2023. [cited by applicant]
U.S. Appl. No. 17/463,473 Office Action dated Dec. 13, 2021. [cited by applicant]
U.S. Appl. No. 17/463,484 Office Action dated Jan. 4, 2022. [cited by applicant]
U.S. Appl. No. 17/843,705 Office Action dated Feb. 9, 2024. [cited by applicant]
U.S. Appl. No. 18/130,757 Office Action dated Jan. 24, 2024. [cited by applicant]
Usman, Nassim et al. Exploiting the Chemical Synthesis of RNA. Trends in Biochemical Sciences 17:334-339 (1992). [cited by applicant]
Van Deutekom et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10(15):1547-54 (2001). [cited by applicant]
Van Vliet et al. Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy. BMC Medical Genetics 9:105 (2008). [cited by applicant]
Verma, Sandeep et al. Modified Oligonucleotides: Synthesis and Strategy for Users. Annual Review of Biochemistry 67:99-134 (1998). [cited by applicant]
Walker et al. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharmaceutical research 12(10):1548-1553 (1995). [cited by applicant]
Ward, E Sally et al. Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]
Wigler, Michael et al. Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell 11(1):223-232 (1977). [cited by applicant]
Wigler, Michael et al. Transformation of Mammalian Cells With an Amplifiable Dominant-acting Gene. PNAS USA 77(6):3567-3570 (1980). [cited by applicant]
Wu, Bin et al. Building Complex Glycopeptides: Development of a Cysteine-free Native Chemical Ligation Protocol. Angewandte Chemie 45(25):4116-4125 (2006). [cited by applicant]
Wu et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35(15):5182-5191 (2007). [cited by applicant]
Wu, George Y. et al. Delivery systems for Gene Therapy. Biotherapy 3(1):87-95 (1991). [cited by applicant]
Wu, Peng et al. Site-specific Chemical Modification of Recombinant Proteins Produced in Mammalian Cells by Using the Genetically Encoded Aldehyde Tag. PNAS USA 106(9):3000-3005 (2009). [cited by applicant]
Xia et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 24(12):2309-16 (2007). [cited by applicant]
Cited By (1)
US 12,648,998